New epilepsy drug tested as standalone treatment
NCT ID NCT06453213
First seen Jun 25, 2026 · Last updated Jul 23, 2026 · Updated 3 times
Summary
This study tests whether cenobamate, already approved for epilepsy, works well when used alone in adults with partial-onset seizures. About 49 participants will take either 100 mg or 200 mg daily, and researchers will track how many become seizure-free for 26 weeks. The goal is to gather more data on its effectiveness as a monotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cenobamate
- What this could lead to
- If successful, this could confirm cenobamate as a reliable monotherapy option for adults with partial-onset seizures, offering better seizure control.
- What could go wrong
- This is a small, open-label Phase 4 study with no placebo group, so results may be less definitive. Some people may still have seizures or side effects like dizziness or drowsiness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOCAL ONSET SEIZURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Arizona Neuroscience Research
Phoenix, Arizona, 85032, United States
-
Bluegrass Epilepsy Research LLC
Lexington, Kentucky, 40504, United States
-
Center For Neurosciences
Tucson, Arizona, 85718, United States
-
Clinical Trials Inc
Little Rock, Arkansas, 72205, United States
-
Consultants In Epilepsy and Neurology
Boise, Idaho, 83702, United States
-
DHR Health Institute for Research and Development
Edinburg, Texas, 78539, United States
-
Elite Clinical Research
Miami, Florida, 33144, United States
-
Hartford Hospital
Hartford, Connecticut, 06102, United States
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Hoag Physician Partners
Newport Beach, California, 92663, United States
-
John Hopkins Epilepsy Center
Baltimore, Maryland, 21287, United States
-
Knight Neurology
Rockledge, Florida, 32955, United States
-
Louisiana State University Health Sciences
Shreveport, Louisiana, 71103, United States
-
Mount Sinai Hospital
New York, New York, 10029, United States
-
NY Neurology Associates
New York, New York, 10003, United States
-
Neuro Pain Medical Center
Fresno, California, 93710, United States
-
University of Missouri Health Care
Columbia, Missouri, 65212, United States
-
Wayne Neurology PLC
Plymouth, Michigan, 48170, United States
-
Yale School of Medicine - Yale-New Haven Hospital
New Haven, Connecticut, 06519, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.